Medicines Co. (MDCO) Misses Q3 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
The Medicines Company Reports Third-Quarter 2019 Financial Results and Achievement of Major Milestones for Inclisiran
October 30, 2019 7:00 AM EDT- Inclisirans pivotal Phase 3 LDL-C lowering clinical trials program successfully completed, and each study met all primary and secondary endpoints
- Phase 3 data reinforced durable, potent efficacy and excellent safety
- ORION-11 results presented at ESC Congress 2019
- ORION-9 and ORION-10 topline results announced, with detailed data presentations to occur at the upcoming American Heart Association Scientific Sessions 2019
- Validation of manufacturing batches completed
PARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company... More
